Pfizer’s most recent trend suggests a bullish bias. One trading opportunity on Pfizer is a Bull Put Spread using a strike $49.00 short put and a strike $44.00 long put offers a potential 13.9% return on risk over the next 24 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $49.00 by expiration. The full premium credit of $0.61 would be kept by the premium seller. The risk of $4.39 would be incurred if the stock dropped below the $44.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Pfizer is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Pfizer is bullish.
The RSI indicator is at 73.31 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Pfizer
Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Mon, 22 Nov 2021 11:45:00 +0000
NEW YORK & MAINZ, Germany, November 22, 2021–Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq:BNTX) today announced topline results from a longer-term analysis of the safety and efficacy of their COVID-19 vaccine in individuals 12 through 15 years of age. The updated findings from the companies’ pivotal Phase 3 trial show that a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-µg per dose) was 100% effective against COVID-19, measured seven days through over four months after the secon
3 No-Brainer Stocks to Buy With $1,000 Right Now
Mon, 22 Nov 2021 11:00:00 +0000
Pfizer (NYSE: PFE) hasn’t been a big market winner in the past. For instance, last year the stock was little changed in spite of the launch of Pfizer’s coronavirus vaccine. First of all, Pfizer has taken the position as leader in the vaccine market.
Germany has enough mRNA shots to meet vaccine demand- Spahn
Mon, 22 Nov 2021 09:38:53 +0000
Health Minister Jens Spahn sought to allay concerns on Monday that Germany was running out of BioNTech/Pfizer vaccine shots, saying that enough supplemental Moderna doses were available to meet demand during the remainder of the year. Spahn said Germany has a combined 50 million doses from BioNTech and Moderna available until the end of the year, which is enough for first and second shots as well as boosters.
1 Cancer Stock on Buyout Watch in 2022
Sun, 21 Nov 2021 14:45:00 +0000
The pharmaceutical industry appears poised for a record-breaking level of merger and acquisition (M&A) activity in 2022. First, Pfizer (NYSE: PFE) and Moderna are both flush with cash thanks to their novel coronavirus vaccines. Third, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Gilead Sciences, Johnson & Johnson, Merck, Moderna, Pfizer, and Sanofi are all expected to pursue bolt-on acquisitions next year to flesh out their clinical pipelines and product portfolios.
How Good Were BioNTech’s Q3 Results?
Sun, 21 Nov 2021 14:01:00 +0000
BioNTech (NASDAQ: BNTX) announced its third-quarter results on Nov. 9. In this Motley Fool Live video recorded on Nov. 10, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss those results. Keith Speights: Well, Brian, we talked about earlier, we’re still in the thick of earnings season, and BioNTech announced its Q3 results on Tuesday.
Follow Us on Facebook